Notch intracellular domain (NICD)

The Notch intracellular domain (NICD) is the signaling-active fragment released from Notch receptors (Notch 1, 2, 3, or 4) following ligand-induced proteolytic cleavage. This process is initiated by the binding of Delta-like or Jagged ligands, which triggers sequential cleavages, the final one being mediated by the gamma-secretase enzyme complex (Source: UniProt P46531). Once released into the cytoplasm, the NICD translocates to the nucleus where it functions as a transcriptional co-activator by binding to the DNA-binding protein RBPJ (CBF1) and recruiting Mastermind-like (MAML) proteins (Source: PubMed 25304310). This transcriptional complex activates genes essential for cell fate specification, tissue patterning, and cellular growth (Source: NIH StatPearls). Dysregulation of the NICD, often through gain-of-function mutations or over-activation of the pathway, is a primary driver in several malignancies, including T-cell acute lymphoblastic leukemia and desmoid tumors (Source: PubMed 37151125). Pharmacological targeting of the NICD primarily involves gamma-secretase inhibitors (GSIs) that prevent its formation, though these therapies often face challenges due to significant gastrointestinal side effects resulting from the systemic inhibition of Notch signaling (Source: PubMed 21460879).

Other names

Active NotchNotch ICDCleaved NotchNCIDNotch intracellular fragment

Inhibition of NICD generation through the blocking of gamma-secretase proteolytic activity or the disruption of the NICD/RBPJ/MAML transcriptional activator complex.